Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Taboada
PL02.01 Overall Survival With Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results From PACIFIC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - Update From PACIFIC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab in Patients With Unresectable Stage III NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Durvalumab Extends OS in NSCLC
Cancer Discovery
Oncology
Improved Overall Survival in Patients With Grade III and IV Acute Graft-Versus-Host Disease
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Better Overall Survival With Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
PD-L1-Antikörper Durvalumab Verlängert Überleben Bei NSCLC Im Stadium III
Pneumologie
Medicine
Pulmonary
Respiratory Medicine
122P Pathological Response Rates After Induction Radio-Chemotherapy in Stage III NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Oncologic Outcomes of Postoperative Chemoradiotherapy Versus Chemotherapy Alone in Stage II and III Upper Rectal Cancer
Annals of Coloproctology
Gastroenterology
